Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Artiflex foldable phakic intraocular lens for the correction of moderate to high myopia: ten year follow-up results

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Intraocular Refractive Results

Venue: Poster Village: Pod 2

First Author: : I.Carneiro PORTUGAL

Co Author(s): :    P. Batista   V. Lages   M. Lume   R. Salgado   M. Pinto  

Abstract Details


To evaluate the long-term efficacy, predictability and safety of the foldable Artiflex phakic intraocular lens for the correction of myopia.


Department of Ophthalmology of a tertiary referral center in Oporto, Portugal – Centro Hospitalar Universitário do Porto.


Retrospective study of 33 eyes of 18 patients implanted with an Artiflex pIOL. Mean implanted spherical powers was -8.0 diopters (D) (range from -6.0 to -10.5 D). Total follow-up was 10 years. Outcome parameters included uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), intraocular pressure, endothelial cell density (ECD) and complications. Comparisons were made between preoperative clinical data and the clinical data at 1, 5 and 10 years after surgery.


The mean spherical equivalent (SE) after 10 years was -0.10 ± 0.2 D, with no significant change in mean SE between 1, 5 and 10 years. At 10 years, 91% of eyes had a UCVA of >20/40 and postoperative UCVA was equal to or better than preoperative BCVA in 82 % of eyes. Nine percent of eyes gained 1 or more Snellen lines of BSCVA, at 10 years. The mean endothelial cell loss was 141 (range from 82 to 920) at 10 years. The mean intraocular pressure remained stable at 14 ± 2 mmHg and few complications were identified.


The Artiflex pIOL effectively and safely corrects myopia in the long term, with stable and predictable visual results after 10 years, when strict inclusion criteria are applied. There was no significant loss of corneal endothelial cells and very few complications were reported.

Financial Disclosure:


Back to previous